Full Title
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tarlatamab in Combination with AB248 in Participants with Extensive Stage Small Cell Lung Cancer (DeLLphi-311)Purpose
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Contact
For more information or to see if you can join this study, please call Dr. Mark Awad’s office at 646-608-4371.
Protocol
26-055
Phase
Phase I (phase 1)
Disease Status
Relapsed or Refractory
Investigator
Co-Investigators
Diseases
ClinicalTrials.gov ID
NCT07037758